Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Advanced Search

Search

You could also try: mistake (35), fault (22), slip (31)

Avelumab(800mg)

Description: Chemotherapy Protocol BLADDER CANCER AVELUMAB (800mg) Regimen  Bladder Cancer - Avelumab Indication  Avelumab is indicated as monotherapy for the first-line maintenance
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Bladdercancer/Avelumab800mg.pdf

Carfilzomib-Dexamethasone(20) Ver1

Description: Chemotherapy Protocol MYELOMA Carfilzomib-Dexamethasone (20) Regimen • Myeloma – Carfilzomib-Dexamethasone (20) Indication • Carfilzomib in combination with dexamethasone is an option for
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/carfilzomib-dexamethasone20-ver1.pdf

Carfilzomib(14 day)-Dexamethasone(20) Ver1

Description: Chemotherapy Protocol MYELOMA Carfilzomib (14 day)-Dexamethasone (20) Regimen  Myeloma – Carfilzomib-Dexamethasone (20) Indication  Carfilzomib in combination with dexamethasone is an
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/carfilzomib14-day-dexamethasone20-ver1.pdf

Cataracts - patient information

Description: This factsheet explains what cataracts are and how they are treated.
Url: /Media/UHS-website-2019/Patientinformation/Eyes/Cataracts-3040-PIL.pdf

Apalutamide v1

Description: Chemotherapy Protocol PROSTATE APALUTAMIDE Regimen  Prostate cancer Indication  Apalutamide is recommended for non-metastatic prostate cancer as defined by recent imaging
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Prostatecancer/Apalutamide-v1.pdf

MyelomaBortezomib IV DexamethasonePabinostatThalidomide 21day Ver1.1

Description: Chemotherapy Protocol MULTIPLE MYELOMA BORTEZOMIB (IV)-DEXAMETHASONE-PANOBINOSTAT-THALIDOMIDE Regimen (21 day) • Multiple Myeloma – Bortezomib (IV)-Dexamethasone-Panobinostat-Thalidomide (21 day
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/MyelomaBortezomib-IV-DexamethasonePabinostatThalidomide-21day-Ver1.1.pdf

DVdSC (weekly cycles 9 onwards) DaratumumabSC-Bortezomib-Dexamethasone Ver1

Description: Chemotherapy Protocol Myeloma DVd SC (weekly) Bortezomib Daratumumab Dexamethasone Cycles 9 onwards Regimen • Myeloma – Bortezomib with daratumumab and dexamethasone Indication • Daratumumab
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/DVdSC-weekly-cycles-9-onwards-DaratumumabSC-Bortezomib-Dexamethasone-Ver1.pdf

Durvalumab_14day

Description: Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) Durvalumab (14 day) Regimen • NSCLC - Durvalumab (14 day) Indication • Stage 3 NSCLC after
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Durvalumab-14day.pdf

Durvalumab(28day-1500mg)

Description: Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) Durvalumab (28 day – 1500mg) Regimen • NSCLC - Durvalumab (28 day – 1500mg) Indication • Durvalumab is
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Durvalumab28day-1500mg.pdf

Docetaxel-Nintedanib v1

Description: Chemotherapy Protocol NSCLC CANCER DOCETAXEL-NINTEDANIB Regimen NSCLC – Docetaxel-Nintedanib Indication Advanced or metastatic NSCLC of adenocarcinoma origin that has progressed
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Docetaxel-Nintedanib-v1.pdf

341 to 350 of 630

Previous … 33 34 35 36 37 … Next